Genomic profiling screens small molecules of metastatic prostate carcinoma

Xu,Axiang; Sun,Shengkun

doi:10.3892/ol.2015.3472

Genomic profiling screens small molecules of metastatic prostate carcinoma

Authors:
- Axiang Xu
- Shengkun Sun
View Affiliations

Affiliations: Department of Urology, People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/ol.2015.3472
Pages: 1402-1408
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the pathogenesis of metastatic prostate carcinoma, to find the metabolic pathways changed in the disease and to screen out the potential therapeutic drugs. GSE38241 was downloaded from Gene Expression Omnibus; the Geoquery package was applied to preprocessed expression profiling, and the differentially‑expressed genes (DEGs) were selected with limma (linear regression model packages). Next, WikiPathways cluster analysis was performed for DEGs on a Gene Set Analysis Toolkit V2 platform, and DEGs with hypergeometric algorithms were calculated through gene set enrichment analysis. A total of 1,126 DEGs were identified between the normal prostate and metastatic prostate carcinoma. In addition, KPNA4, SYT1, PLCB1, SPRED1, MBNL2, RNF165, MEF2C, MBNL1, ZFP36L1 and CELF2, were found to be likely to play significant roles in the process of metastatic prostate carcinoma. The small molecules STOCK1N‑35874 and 5182598 could simulate the state of normal cells well, while the small molecules MS‑275 and quinostatin could simulate the state of metastatic prostate carcinoma cells. In conclusions, the small molecules STOCK1N‑35874 and 5182598 were identified to be good potential therapeutic drugs for the treatment of metastatic prostate carcinoma, while the two small molecules MS-275 and quinostatin could cause metastatic prostate carcinoma.

View Figures

View References

1	Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, et al: PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 69:532–535. 2007. View Article : Google Scholar : PubMed/NCBI
2	Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, et al: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst. 104:125–132. 2012. View Article : Google Scholar : PubMed/NCBI
3	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 366:981–990. 2012. View Article : Google Scholar : PubMed/NCBI
4	Alhasan AH, Kim DY, Daniel WL, Watson E, Meeks JJ, Thaxton CS and Mirkin CA: Scanometric MicroRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates. Anal Chem. 84:4153–4160. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA and Schalken JA: DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 44:8–15. 2003. View Article : Google Scholar : PubMed/NCBI
6	Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1401–1408. 1997. View Article : Google Scholar : PubMed/NCBI
7	Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, et al: Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci USA. 110:E1604–E1612. 2013. View Article : Google Scholar : PubMed/NCBI
8	Lee C, Zhang Q, Zi X, Dash A, Soares MB, Rahmatpanah F, Jia Z, McClelland M and Mercola D: TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol. 1:78–88. 2012.PubMed/NCBI
9	Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK and Batra SK: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene. 29:1293–1302. 2010. View Article : Google Scholar : PubMed/NCBI
10	Jin JK, Dayyani F and Gallick GE: Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI
11	Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, et al: DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 5:169ra1102013. View Article : Google Scholar
12	R Development Core Team, . R: A Language and Environment for Statistical Computing. http://www.r-project.org/R Foundation for Statistical Computing; Vienna, Austria: 2008
13	Davis S and Meltzer PS: GEOquery: A bridge between the gene expression omnibus (GEO) and BioConductor. Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
14	Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
15	Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, et al: NCBI GEO: Archive for functional genomics data sets-10 years on. Nucleic Acids Res. 39:D1005–D1010. 2011. View Article : Google Scholar : PubMed/NCBI
16	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:: 2004.PubMed/NCBI
17	Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT and Pico AR: WikiPathways: Building research communities on biological pathways. Nucleic Acids Res. 40:D1301–D1307. 2012. View Article : Google Scholar : PubMed/NCBI
18	Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR and Evelo C: WikiPathways: Pathway editing for the people. PLoS Biol. 6:e1842008. View Article : Google Scholar : PubMed/NCBI
19	Zhang B, Kirov S and Snoddy J: WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33:W741–W748. 2005. View Article : Google Scholar : PubMed/NCBI
20	Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011. View Article : Google Scholar : PubMed/NCBI
21	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological). 57:289–300. 1995.
22	Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al: The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science. 313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
23	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
24	Baldi P and Long AD: A Bayesian framework for the analysis of microarray expression data: Regularized t-test and statistical inferences of gene changes. Bioinformatics. 17:509–519. 2001. View Article : Google Scholar : PubMed/NCBI
25	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
26	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
27	Amankwah EK, Sellers TA and Park JY: Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 33:1259–1269. 2012. View Article : Google Scholar : PubMed/NCBI
28	Hinoi E, Nakamura Y, Takada S, Fujita H, Iezaki T, Hashizume S, Takahashi S, Odaka Y, Watanabe T and Yoneda Y: Growth differentiation factor-5 promotes brown adipogenesis in systemic energy expenditure. Diabetes. 63:162–175. 2013. View Article : Google Scholar : PubMed/NCBI
29	Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, et al: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 188:97–113. 2002. View Article : Google Scholar : PubMed/NCBI
30	Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, Swanson MS and Thornton CA: Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet. 15:2087–2097. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hao M, Akrami K, Wei K, De Diego C, Che N, Ku JH, Tidball J, Graves MC, Shieh PB and Chen F: Muscleblind-like 2 (Mbnl2)-deficient mice as a model for myotonic dystrophy. Dev Dyn. 237:403–410. 2008. View Article : Google Scholar : PubMed/NCBI
32	Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z, Doi H, Matsumoto S, Kondo N, Iida M, et al: Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 18:1136–1141. 2012. View Article : Google Scholar : PubMed/NCBI
33	Braunagel SC, Williamson ST, Ding Q, Wu X and Summers MD: Early sorting of inner nuclear membrane proteins is conserved. Proc Natl Acad Sci USA. 104:9307–9312. 2007. View Article : Google Scholar : PubMed/NCBI
34	Stumpo DJ, Byrd NA, Phillips RS, Ghosh S, Maronpot RR, Castranio T, Meyers EN, Mishina Y and Blackshear PJ: Chorioallantoic fusion defects and embryonic lethality resulting from disruption of Zfp36L1, a gene encoding a CCCH tandem zinc finger protein of the Tristetraprolin family. Mol Cell Biol. 24:6445–6455. 2004. View Article : Google Scholar : PubMed/NCBI
35	Yamazaki T, Kawamura Y, Minami A and Uemura M: Calcium-dependent freezing tolerance in Arabidopsis involves membrane resealing via synaptotagmin SYT1. Plant Cell. 20:3389–3404. 2008. View Article : Google Scholar : PubMed/NCBI
36	Poduri A, Chopra SS, Neilan EG, Elhosary PC, Kurian MA, Meyer E, Barry BJ, Khwaja OS, Salih MA, Stödberg T, et al: Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 53:e146–e150. 2012. View Article : Google Scholar : PubMed/NCBI
37	Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, et al: Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 39:1120–1126. 2007. View Article : Google Scholar : PubMed/NCBI
38	Kelly CE, Thymiakou E, Dixon JE, Tanaka S, Godwin J and Episkopou V: Rnf165/Ark2C enhances BMP-Smad signaling to mediate motor axon extension. PLoS Biol. 11:e10015382013. View Article : Google Scholar : PubMed/NCBI
39	Wink M: Molecular modes of action of cytotoxic alkaloids: from DNA intercalation, spindle poisoning, topoisomerase inhibition to apoptosis and multiple drug resistance. Alkaloids Chem Biol. 64:1–47. 2007. View Article : Google Scholar : PubMed/NCBI
40	Mei L, Chen Y, Wang Z, Wang J, Wan J, Yu C, Liu X and Li W: Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21. Br J Pharmacol. 172:2232–2245. 2015. View Article : Google Scholar : PubMed/NCBI
41	Solomon VR and Lee H: Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem. 18:1488–1508. 2011. View Article : Google Scholar : PubMed/NCBI
42	Cordell GA, Quinn-Beattie ML and Farnsworth NR: The potential of alkaloids in drug discovery. Phytother Res. 15:183–205. 2001. View Article : Google Scholar : PubMed/NCBI